Does the use of leucocyte depletion during cardiopulmonary bypass affect exhaled nitric oxide production?

Perfusion

Volumn 19, Issue 1, 2004, Pages 7-10

  Sheppard, Stuart V ^a   Gibbs, R V ^b   Smith, D C ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE;

ADULT; AGED; ANALYZER; ARTICLE; CARDIOPULMONARY BYPASS; CELL SEPARATION; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPLETION; EXHALATION; EXPIRED AIR; HEART MUSCLE REVASCULARIZATION; HUMAN; LEUKOCYTE COUNT; MALE; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

AGED; CARDIOPULMONARY BYPASS; EXHALATION; EXTRACORPOREAL CIRCULATION; FILTRATION; HUMANS; INTRAOPERATIVE PERIOD; LEUKAPHERESIS; LEUKOCYTES; MIDDLE AGED; NITRIC OXIDE; PROSPECTIVE STUDIES;

EID: 1642406021     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1191/0267659104pf703oa     Document Type: Article

References (23)

1. Westaby S. Aspects of biocompatibility in cardiopulmonary bypass. In Williams DF ed. Critical reviews in biocompatibility. Boca Raton, FL: CRC Press, 1987: 193-234.
2. Vaage J. Microvascular injury induced by intravascular platelet aggregation: an experimental study. Scand J Thorac Cardiovasc Surg 1994; 28: 127-33.
3. Parker DJ, Cantrell JW, Karp RB, Stroud RM, Digerness SB. Changes in serum complement and immunoglobulins following cardiopulmonary bypass. Surgery 1972; 71: 824-27.
4. Parker DJ, Cook S, Turner-Warwick M. Serum complement studies during and following cardiopulmonary bypass. In Junod AF, de Haller R eds. Lung metabolism: proteolysis and antiproteolysis, biochemical pharmacology handling of bio-active substances. New York: Academic Press, 1975: 481-87.
5. Tamiya T, Yamasaki M, Maeo Y, Yamashiro T, Ogoshi S, Fujimoto S. Complement activation in cardiopulmonary bypass with special reference to anaphylotoxin production in membrane and bubble oxygenators. Ann Thorac Surg 1988; 46: 47-57.
6. Pekna M, Borowiec J, Fagerhol MK, Venge P, Thelin S. Biocompatibility of heparin-coated circuits used in cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg 1994; 28: 5-11.
7. Ruvolo G, Speziale G, Greco E, et al. Nitric oxide release during hypothermic versus normothermic cardiopulmonary bypass. Eur J Cardiothorac Surg 1995; 9: 651-54.
8. Sato K, Sakamaki T, Sumino H, et al. Rate of nitric oxide release in the lung and factors influencing the concentration of exhaled nitric oxide. Am J Physiol 1996; 270: L914-20.
9. Gourlay T, Fleming J, Taylor KM. Laboratory evaluation of the Pall LG-6 leucocyte depleting arterial line filter. Perfusion 1992; 7: 131-40.
10. Gourlay T, Fleming J, Taylor KM. The effects of pulsatile flow on the leucocyte depleting qualities of the Pall LG-6 leucocyte depleting arterial line filter. Perfusion 1992; 7: 227-32.
11. Thurlow PJ, Doolan L, Sharp R, Sullivan M, Smith B. Studies of the effect of Pall leucocyte filters LG6 and AV6 in an in vitro simulated extracorporeal circulatory system. Perfusion 1995; 10: 291-300.
12. Palanzo DA, Manley NJ, Montesano RM, Yiesley GL, Gordon D. Clinical evaluation of the LeukoGuard (LG-6) arterial line filter for routine open heart surgery. Perfusion 1993; 8: 489-96.
13. Palanzo DA, Manley NJ. Cost effectiveness of using a leuko-depleting arterial line filter. Proc Am Acad Cardiovasc Perf 1994; 15: 124-27.
14. Johnson D, Thomson D, Hurst T, et al. Neutrophil mediated acute lung injury after extracorporeal perfusion. Thorac Cardiovasc Surg 1994; 107: 1193-202.
15. Al-Ebrahim K, Shaffei H. Our experience with using the Pall LG6 leukocyte depleting filter during cardiopulmonary bypass. Ann Thorac Surg 1993; 56: 1216-17.
16. Mihaljevic T, Tonz M, von Segesser LK, et al. The influence of leukocyte filtration during cardiopulmonary bypass on postoperative lung function: a clinical study. J Thorac Cardiovasc Surg 1995; 109: 1138-45.
17. Gustafsson LE, Leone AM, Persson M, et al. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea-pigs, and humans. Biochem Biophys Res Commun 1991; 181: 852-57.
18. kharitonov SA, Yates D, Robbins RA, et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994; 343: 133-35.
19. Massaro AF, Mehta S, Lilly CM, et al. Elevated nitric oxide concentrations in isolated lower airways gas of asthmatic subjects. Am J Respir Crit Care Med 1996; 153: 1510-14.
20. Kharitonov S, Barnes PJ. Nitric oxide in exhaled air is a new marker of airway inflammation. Arch Chest Dis 1996; 51: 533-37.
21. Jilma B, Kastner J, Mensik C, et al. Sex differences in concentrations of exhaled nitric oxide and plasma nitrate. Life Sci 1996; 58: 469-76.
22. Schedin U, Frostell C, Persson MG, Jakobsson J, Andersson G, Gustafsson LE. Contribution from upper and lower airways to exhaled endogenous nitric oxide in humans. Acta Physiol Scand 1995; 39: 327-32.
23. Hussain SN, Abdul-Hussain MN, el-Dwairi Q. Exhaled nitric oxide as a marker for serum nitric oxide concentration in acute endotoxemia. J Crit Care 1996; 11: 167-75.